Circulating galectin-3 correlates with angiogenetic factors, indicators of nutritional condition and systemic inflammation in patients with thyroid cancer

Background and Aims: Several investigators have reported the significance of circulating galectin-3 in thyroid cancer patients. However, the precise meaning of circulating galectin-3 remains unclear. The aim of this study was to investigate the relationships between serum galectin-3 levels and angiogenetic factors, and nutritional and inflammatory indicators in patients with thyroid cancer. Materials and Methods: Sixty-one patients with thyroid tumors were enrolled, comprising 47 pre-treatment thyroid cancer patients and 14 patients with benign thyroid diseases. Galectin-3, interleukin (IL)-6, vascular endothelial growth factor, granulocyte colony-stimulating factor (G-CSF), soluble form of intercellular adhesion molecule-1 (sICAM-1), retinol binding protein, prealbumin, albumin, and transferrin were measured. C-reactive protein (CRP), neutrophil count, lymphocyte count, and neutrophil/lymphocyte ratio (NLR) were also investigated. Results: The amounts of circulating galectin-3 in benign disease and thyroid cancer were significantly higher than those of healthy volunteers (P < 0.001). Analysis of galectin-3 performance in distinguishing malignant disease from benign disease using a receiver operating characteristic curve revealed that the area under the curve was 0.555. There were statistically significant correlations between the circulating amount of galectin-3 and IL6, G-CSF, and sICAM-1. Serum galectin-3 showed statistically significant correlations with albumin, prealbumin, and transferrin. Circulating galectin-3 exhibited strong correlations with CRP, neutrophil count, lymphocyte count, and NLR. Conclusions: Galectin-3 may be one of the key factors in the regulation of angiogenesis, inflammation, and nutrition.

[1]  A. Shivarudrappa,et al.  Galectin-3 Immunohistochemical Expression in Thyroid Neoplasms. , 2015, Journal of clinical and diagnostic research : JCDR.

[2]  E. Lee,et al.  Analysis of RAS mutation and PAX8/PPARγ rearrangements in follicular-derived thyroid neoplasms in a Korean population: frequency and ultrasound findings , 2015, Journal of Endocrinological Investigation.

[3]  E. Yılmaz,et al.  Serum Galectin-3: diagnostic value for papillary thyroid carcinoma. , 2015, Ulusal cerrahi dergisi.

[4]  Yunhui Li,et al.  Serum Galectin-3 as a Potential Marker for Gastric Cancer , 2015, Medical science monitor : international medical journal of experimental and clinical research.

[5]  R. Sun,et al.  Tumor-released Galectin-3, a Soluble Inhibitory Ligand of Human NKp30, Plays an Important Role in Tumor Escape from NK Cell Attack , 2014, The Journal of Biological Chemistry.

[6]  A. Raz,et al.  Galectin-3 in angiogenesis and metastasis. , 2014, Glycobiology.

[7]  M. Schlumberger,et al.  Progress in molecular-based management of differentiated thyroid cancer , 2013, The Lancet.

[8]  C. Chen,et al.  Increased Circulation of Galectin-3 in Cancer Induces Secretion of Metastasis-Promoting Cytokines from Blood Vascular Endothelium , 2013, Clinical Cancer Research.

[9]  M. Bullock,et al.  Serum biomarkers of papillary thyroid cancer , 2013, Journal of Otolaryngology - Head & Neck Surgery.

[10]  R. Ni,et al.  The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma , 2012, Journal of Cancer Research and Clinical Oncology.

[11]  L. Santarpia,et al.  RET TKI: Potential Role in Thyroid Cancers , 2012, Current Oncology Reports.

[12]  Suk-Kyeong Kim,et al.  The BRAFV600E mutation is associated with malignant ultrasonographic features in thyroid nodules , 2011, Clinical endocrinology.

[13]  S. Tsuboi,et al.  A novel strategy for evasion of NK cell immunity by tumours expressing core2 O‐glycans , 2011, EMBO Journal.

[14]  M. Nikiforova,et al.  Both BRAF V600E Mutation and Older Age (≥65 Years) are Associated with Recurrent Papillary Thyroid Cancer , 2011, Annals of Surgical Oncology.

[15]  Thijs J. Hagenbeek,et al.  Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes , 2010, Proceedings of the National Academy of Sciences.

[16]  I. Paunovíc,et al.  Serum Cyfra 21.1 and galectin-3 protein levels in relation to immunohistochemical cytokeratin 19 and galectin-3 expression in patients with thyroid tumors , 2010, Journal of Cancer Research and Clinical Oncology.

[17]  A. Miyauchi,et al.  Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies. , 2008, Biochemical and biophysical research communications.

[18]  F. Pattou,et al.  Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. , 2008, Thyroid : official journal of the American Thyroid Association.

[19]  H. Kanayama,et al.  Serum level of galectin-3 in human bladder cancer. , 2008, The journal of medical investigation : JMI.

[20]  D. Hsu,et al.  Toxoplasma gondii infection reveals a novel regulatory role for galectin-3 in the interface of innate and adaptive immunity. , 2006, The American journal of pathology.

[21]  G. Ghanem,et al.  High serum galectin‐3 in advanced melanoma: preliminary results , 2006, Clinical and experimental dermatology.

[22]  A. Raz,et al.  Galectin-3 enhances cyclin D1 promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells , 2002, Oncogene.

[23]  Isabelle Camby,et al.  Galectins and cancer. , 2002, Biochimica et biophysica acta.

[24]  Michael J. Davis,et al.  Shuttling of galectin-3 between the nucleus and cytoplasm. , 2002, Glycobiology.

[25]  Lana Barkin “Dis-ease”: , 2000, Ritual, Myth, and Mysticism in the Work of Mary Butts.

[26]  N. Tinari,et al.  Concentrations of galectin-3 in the sera of normal controls and cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  H. Inohara,et al.  Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. , 1997, Cancer Research.

[28]  H. Matsuda,et al.  Rapid turnover proteins as a prognostic indicator in cancer patients , 1995, Surgery Today.

[29]  L. Delbridge,et al.  Increasing incidence and changing presentation of thyroid cancer over a 30‐year period , 1995, The British journal of surgery.

[30]  J. Becker,et al.  Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. , 1993, Journal of immunology.

[31]  D. Johnston,et al.  The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. , 1992, The Journal of clinical endocrinology and metabolism.

[32]  J. Becker,et al.  Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. , 1991, Journal of immunology.

[33]  E. Kaplan,et al.  Natural history, treatment, and course of papillary thyroid carcinoma. , 1990, The Journal of clinical endocrinology and metabolism.

[34]  A. Spiekerman,et al.  Prealbumin: a parameter of visceral protein levels during albumin infusion. , 1982, JPEN. Journal of parenteral and enteral nutrition.

[35]  F. Delpeuch,et al.  The effect of iron-deficiency anaemia on two indices of nutritional status, prealbumin and transferrin , 1980, British Journal of Nutrition.

[36]  G. Bozkaya,et al.  Prognostic Significance of Serum Galectin-3 Levels in Patients with Hepatocellular Cancer and Chronic Viral Hepatitis , 2015, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.

[37]  M. Notarnicola,et al.  Serum levels of galectin-3 and its ligand 90k/mac-2bp in colorectal cancer patients. , 2010, Immunopharmacology and immunotoxicology.

[38]  R. Kiss,et al.  The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. , 2008, Oral oncology.

[39]  D. Kerr,et al.  The epidemiology of thyroid carcinoma. , 1993, Critical reviews in oncogenesis.

[40]  N. Trapeznikov,et al.  [General mechanisms of metastasis of malignant neoplasms into bones]. , 1977, Khirurgiia.